Drugs / MT-401-OTS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06552416 | Jun 2025 → Sep 2029 expected | acute myeloid leukemia, myelodysplastic syndrome | Marker Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-06 | Marker Therapeutics, Inc. | Results Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program markertherapeutics.com ↗
The therapy was well tolerated with no treatment-related adverse events. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-06 | Marker Therapeutics, Inc. | Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program markertherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-401-OTS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06552416 ↗ |
| Modality | Cell therapy | “off the shelf cellular therapy product” NCT06552416 ↗ |
| Route | Intravenous | “given by IV infusion” NCT06552416 ↗ |